p27kip1: A New Multiple Endocrine Neoplasia Gene?

被引:46
|
作者
Marinoni, Ilaria [1 ]
Pellegata, Natalia S. [1 ]
机构
[1] Helmholtz Zentrum Munchen, Inst Pathol, DE-85764 Neuherberg, Germany
关键词
Multiple endocrine neoplasia; p27kip1; Cell cycle regulation; KINASE INHIBITOR P27; P27(KIP1) MESSENGER-RNA; GERM-LINE MUTATIONS; CDK INHIBITORS; CELL-MIGRATION; BREAST-CANCER; PITUITARY-ADENOMAS; TUMOR SUPPRESSION; PROSTATE-CANCER; EXPRESSION;
D O I
10.1159/000320366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple endocrine neoplasias (MEN) are autosomal dominant disorders characterized by the occurrence of tumors in at least two endocrine glands. Two types of MEN syndromes have long been known: MEN type 1 (MEN1) and MEN type 2 (MEN2), associated with a different spectrum of affected organs. MEN1 and MEN2 are caused by germline mutations in the MEN1 tumor suppressor gene and the RET proto-oncogene, respectively. Lately, a new type of MEN was identified (named MEN4) which is due to mutations in the CDKN1B gene, encoding for p27kip1 (p27), a cyclin-dependent kinase (Cdk) inhibitor that regulates the transition of cells from G1 to S phase. p27 is a non-canonical tumor suppressor since it is usually not somatically mutated in human cancers but it is often downregulated by post-translational mechanisms. The discovery of MEN4 has defined a new role for CDKN1B as a tumor susceptibility gene for multiple endocrine tumors. To date, six germline CDKN1B mutations have been found in patients with a MEN1-like phenotype but negative for MEN1 mutations. Due to the limited number of patients so far identified, the phenotypic features of MEN4 are not clearly defined. Here, we review the clinical and molecular characteristics of the MEN4 syndrome and summarize the main functions of p27 to better comprehend how their alteration can predispose to neuroendocrine tumors. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:19 / 28
页数:10
相关论文
共 50 条
  • [31] CDKI p27kip1与肿瘤
    王刚
    现代妇产科进展, 1999, (04) : 360 - 363
  • [32] Expression and hypermethylation of p27kip1 in hepatocarcinogenesis
    Pu-Ping Lei
    World Journal of Gastroenterology, 2005, (29) : 4587 - 4591
  • [33] Enzymatic modification of p27kip1 by transglutaminase
    Patel, Raj
    Crawford, Wade
    Wilson, Eric
    Sheaff, Robert
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [34] Regulatuion of Cdk inhibitor p27Kip1
    Tomoda, K
    Kato, N
    Kato, JY
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 26P - 26P
  • [35] A second RING to destroy p27Kip1
    Ludger Hengst
    Nature Cell Biology, 2004, 6 : 1153 - 1155
  • [36] Expression of p27kip1 in prostatic adenocarcinoma
    Cheville, JC
    Lloyd, RV
    Sebo, TJ
    Cheng, L
    Erickson, L
    Bostwick, DG
    Lohse, CM
    Wollan, P
    MODERN PATHOLOGY, 1998, 11 (04) : 324 - 328
  • [37] p27kip1与妇科肿瘤
    张宣
    国外医学妇产科学分册., 2003, (01) : 47 - 49
  • [38] A second RING to destroy p27Kip1
    Hengst, L
    NATURE CELL BIOLOGY, 2004, 6 (12) : 1153 - 1155
  • [39] Another piece of the p27Kip1 puzzle
    Kaldis, Philipp
    CELL, 2007, 128 (02) : 241 - 244
  • [40] P27KIP1 IN ACUTE MYELOID LEUKEMIA
    Sucic, M.
    Hodak, N.
    Markovic-Glamocak, M.
    Ries, S.
    Kuvezdic, K. Gjadrov
    Labar, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 506 - 506